Fresenius 

0
988
+€0.00+0% 00:00 今天

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

即將到來

財報

11月4日預期
Q1 2026
Q2 2026
Q3 2026
0.73
0.78
0.83
0.88
預期EPS
0.781819703824064
實際EPS
0.7259891235839999

財務

5.53%利潤率
有盈利
2020
2021
2022
2023
2024
2025
22.87B營收
1.26B淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 FREN.MU 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
顯示更多
執行長
Michael Sen
員工
178486
國家
德國
ISIN
DE000A2TSV53

上市

0 則留言

分享你的想法

常見問題

Fresenius 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Boerse Muenchen 交易所,Fresenius 的股票以代號 FREN.MU 進行交易。
Fresenius 下一次財報日期是什麼時候?▼
Fresenius 將於 2027年2月24日 公布下一次財報。
Fresenius 上一季度的財報如何?▼
FREN.MU 上一季度的財報為每股 0.73 EUR,預估為 0.78 EUR,帶來 -7.14% 的驚喜。下一季度的預估財報為每股 不適用 EUR。
Fresenius 去年的營收是多少?▼
Fresenius 去年的營收為 22.87BEUR。
Fresenius 去年的淨利是多少?▼
FREN.MU 去年的淨收益為 1.26BEUR。
Fresenius 有多少名員工?▼
截至 2026年11月7日,公司共有 178,486 名員工。
Fresenius 位於哪個產業?▼
Fresenius從事於Health & Wellness產業。
Fresenius 何時完成拆股?▼
Fresenius 最近沒有進行任何拆股。
Fresenius 的總部在哪裡?▼
Fresenius 的總部位於 德國 的 Bad Homburg vor der Höhe。